Key result
Systemic sTWEAK application after myocardial infarction in mice reduced left ventricular function and increased mortality, while inhibition with anti-TWEAK antibodies improved function and survival.
Why the study?
Does TWEAK modulation affect left ventricular function and survival in mice after myocardial infarction?
Does TWEAK modulation affect left ventricular function and survival in mice after myocardial infarction?
TWEAK exerts maladaptive effects on left ventricular function and survival after myocardial infarction in mice by reducing metabolic adaptations via PGC-1α inhibition.
BACKGROUND: TNF-like weak inducer of apoptosis (TWEAK) has recently been shown to be potentially involved in adverse cardiac remodeling. However, neither the exact role of TWEAK itself nor of its receptor Fn14 in this setting is known. AIM OF THE STUDY: To analyze the effects of sTWEAK on myocardial function and gene expression in response to experimental myocardial infarction in mice. RESULTS: TWEAK directly suppressed the expression of PGC-1α and genes of oxidative phosphorylation (OXPHOS) in cardiomyocytes. Systemic sTWEAK application after MI resulted in reduced left ventricular function and increased mortality without changes in interstitial fibrosis or infarct size. Molecular analysis revealed decreased phosphorylation of PI3K/Akt and ERK1/2 pathways associated with reduced expression of PGC-1α and PPARα. Likewise, expression of OXPHOS genes such as atp5O, cycs, cox5b, and ndufb5 was also reduced. Fn14-/- mice showed significantly improved left ventricular function and PGC-1α levels after MI compared to their respective WT littermates (Fn14+/+). Finally, inhibition of intrinsic TWEAK with anti-TWEAK antibodies resulted in improved left ventricular function and survival. CONCLUSIONS: TWEAK exerted maladaptive effects in mice after myocardial infarction most likely via direct effects on cardiomyocytes. Analysis of the potential mechanisms revealed that TWEAK reduced metabolic adaptations to increased cardiac workload by inhibition of PGC-1α.
No takes yet. Share an insight, caveat, or question.
Jarr et al. (2014) studied Myocardial infarction. sTWEAK application, Fn14 knockout, or anti-TWEAK antibodies vs. Wild-type littermates (Fn14+/+) or control was evaluated on Left ventricular function and mortality. Systemic sTWEAK application after myocardial infarction in mice reduced left ventricular function and increased mortality, while inhibition with anti-TWEAK antibodies improved function and survival.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: